Alatrofloxacin: Difference between revisions

Alatrofloxacin
Clinical data
Routes of; administration	Intravenous
ATC code	none;
Legal status
Legal status	Withdrawn;
Pharmacokinetic data
Bioavailability	N/A
Protein binding	76% (trovafloxacin)
Metabolism	Quickly hydrolyzed to trovafloxacin
Elimination half-life	9 to 12 hours (trovafloxacin)
Excretion	Fecal and renal (trovafloxacin)
Identifiers
	IUPAC name 7-[(1R,5S)-6-{[(2S)-1-{[(2S)-; 2-aminopropanoyl]amino}-1-oxopropan-2-yl]amino}-; 3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-; 6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;
CAS Number	157182-32-6 157605-25-9 (mesylate);
PubChem CID	5489474;
ChemSpider	21106252 ;
UNII	7QVV6I50DT;
ChEMBL	ChEMBL1201197 ;
Chemical and physical data
Formula	C26H25F3N6O5
Molar mass	558.509 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1ccc(c(F)c1)N/3c2nc(c(F)cc2C(=O)C(\C(=O)O)=C\3)N5C[C@@H]4C(NC(=O)[C@@H](NC(=O)[C@@H](N)C)C)[C@@H]4C5;
	InChI InChI=1S/C26H25F3N6O5/c1-10(30)24(37)33-25(38)11(2)31-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)32-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20,31H,7-8,30H2,1-2H3,(H,39,40)(H,33,37,38)/t10?,11?,14-,15+,20? ; Key:GAJLLIJXQAMBHW-HVOYUNNHSA-N ;
	(what is this?) (verify)

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 00:48, 1 July 2011

Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.^[1] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 that encountered criticism for its Nigerian trials and adverse clinical reactions.^[2]^[3]

Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.

References

^ "PubChem CID 5489474".
^ Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. doi:10.1016/S0753-3322(03)00054-4. PMID 14568230.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ. 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMC 1471980. PMID 16735322.

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

[1] "PubChem CID 5489474".

[2] Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. doi:10.1016/S0753-3322(03)00054-4. PMID 14568230.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[3] Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ. 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMC 1471980. PMID 16735322.

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
-{{Drugbox
+{{drugbox
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = 7QVV6I50DT
 | Verifiedfields = changed
 | verifiedrevid = 399380398

Revision as of 00:48, 1 July 2011

See also

References